What We Do

Cellanyx’s Live Single Cell Phenotypic Test Distinguishes Indolent vs. Aggressive Cancers

Cellanyx has developed a LDT (Laboratory Developed Test) that uniquely analyzes live tumor single cell behavior (phenotype) to stratify the risk of tumor aggressiveness. Prostate cancer risk stratification is most challenging for men with low and intermediate grade prostate cancer. Cellanyx’s LDT, which augments pathologic diagnosis to improve risk stratification, is poised to initiate a clinical utility study to support its commercial introduction.

Proprietary and Patented Phenotypic Technology Platform Uniquely Analyzes Biomarkers of Cancer Morphology and Cell Behavior

Tumor cells behave differently than normal cells. Cellanyx’s platform analyzes phenotypic biomarkers in live single tumor cells that are hallmarks of cancer to allow objective, quantitative and predictive measures of adverse pathology potential. The phenotypic test augments standard histopathology and is distinct from other genetic or genomic tests, which infer risk based on small sets of genes obtained from formalin-fixed paraffin-embedded (FFPE) blocks.

First-in-class Prostate Cancer Phenotypic Test Nearing Commercialization

Prostate cancer is the most common cancer in men, yet relatively few patients die from the disease. Distinguishing aggressive tumors – which require treatment – from indolent ones – which can be monitored through active surveillance – remains a key challenge in prostate cancer disease management.

Pipeline of Proprietary Phenotypic LDTs for Multiple Cancers

In addition to clinically proven prostate cancer phenotypic test, Cellanyx has a pipeline of LDTs for other solid tumors in earlier stages of development, including tests for breast, kidney, bladder and non-small cell lung cancers. The most advanced of these tests is clinically demonstrated for breast cancer and early proof of clinical evidence has been obtained for kidney, bladder and non-small cell lung cancers.

Contact us

Email: info@cellanyx.com


Cellanyx, LLC

100 Cummings Center

Beverly, MA 01915